奈达铂联合多西他赛治疗晚期复治非小细胞肺癌的临床观察

Nedaplatin Combined with Docetaxel in the Treatment of Refractory Advanced Non-Small-Cell Lung Cancer

目的:观察奈达铂联合多西他赛治疗晚期复治非小细胞肺癌的疗效和毒副反应。方法:46例晚期复治非小细胞肺癌患者,采用奈达铂联合多西他赛化疗,其中奈达铂100mg/m^2,静脉滴注,第1天;多西他赛75mg/m^2,静脉滴注,第1天;每3周重复。完成2周期治疗后评价疗效。结果:46例患者共化疗128个周期,全组45例可评价疗效,无CR患者,PR 11例,NC 19例,PD 15例。总有效率为24.44%(11/45),疾病控制率66.67(30/45)。中位TTP为5.5个月,中位生存期(MST)为9个月,1年生存率为41%。主要毒副反应为骨髓抑制。结论:奈达铂联合多西他赛治疗晚期复治非小细胞肺癌有一定的疗效,消化道反应及肾毒性较轻,可选为顺铂或卡铂耐药患者的二线治疗。

Objective： To observe the efficacy and the side effects of the combination of nedaplatin and docetaxel in the treatment of refractory advanced non-small-cell lung cancer（ NSCLC）. Methods： 46 patients with refractory advanced NSCLC were treated with nedaplatin 100mg/m^2 by intravenous infusion on d1 , and docetaxel 75 mg/m^2 by intravenous infusion on dt every 21 days. The efficacy was evaluated after 2 cycles. Results： 46 patients altogether accepted 128 courses of chemotherapy, and 45 cases could be evaluated. No complete response was observed. 11 cases got PR, 19 cases got NC and 15 cases got PD. The overall response rate was 24.44% （ 11/45 ） , and the disease control rate was 66.67% （30/45）. The median time to disease progression was 5.5 months and the median survival time was 9 months. The 1-year survival rate was 41%. The main toxicity was myelosuppression. Conclusion： The combination of nedeplatin and docetaxel is effective in the treatment of refractory advanced NSCLC. The digestive reaction and renal toxicity are mild. The regimen of nedaplatin and docetaxel has reasonable efficacy with moderate toxicity to be chosen as second-line chemotherapy for patients with cisplatin and carboplatin resistance.